Determination of short-chain fatty acids as putative biomarkers of cancer diseases by modern analytical strategies and tools: a review

0574696 - MBÚ 2024 RIV CH eng J - Článek v odborném periodiku
Chalova, P. - Tazky, A. - Škultéty, L'udovít - Minichová, L. - Chovanec, M. - Ciernikova, S. - Mikus, P. - Piešťanský, J.
Determination of short-chain fatty acids as putative biomarkers of cancer diseases by modern analytical strategies and tools: a review.
Frontiers in Oncology. Roč. 13, June 27 (2023), č. článku 1110235. ISSN 2234-943X. E-ISSN 2234-943X
Institucionální podpora: RVO:61388971
Klíčová slova: short-chain fatty acids * cancer * biomarker * mass spectrometry * separation methods * chromatography * capillary electrophoresis
Obor OECD: Microbiology
Impakt faktor: 4.7, rok: 2022
Způsob publikování: Open access
https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2023.1110235/full

Short-chain fatty acids (SCFAs) are the main metabolites produced by bacterial fermentation of non-digestible carbohydrates in the gastrointestinal tract. They can be seen as the major flow of carbon from the diet, through the microbiome to the host. SCFAs have been reported as important molecules responsible for the regulation of intestinal homeostasis. Moreover, these molecules have a significant impact on the immune system and are able to affect inflammation, cardiovascular diseases, diabetes type II, or oncological diseases. For this purpose, SCFAs could be used as putative biomarkers of various diseases, including cancer. A potential diagnostic value may be offered by analyzing SCFAs with the use of advanced analytical approaches such as gas chromatography (GC), liquid chromatography (LC), or capillary electrophoresis (CE) coupled with mass spectrometry (MS). The presented review summarizes the importance of analyzing SCFAs from clinical and analytical perspective. Current advances in the analysis of SCFAs focused on sample pretreatment, separation strategy, and detection methods are highlighted. Additionally, it also shows potential areas for the development of future diagnostic tools in oncology and other varieties of diseases based on targeted metabolite profiling.
Trvalý link: https://hdl.handle.net/11104/0344859